Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 55
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/8/2007
 
First Published:
9/1/1994
1.
Phase III Randomized Study of Adjuvant Tamoxifen With or Without Ovarian Suppression and/or Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) in Premenopausal Women With Stage I-IIIA, Unilateral, Invasive Breast Cancer (Summary Last Modified 12/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
70 and under
SCTN-BR9401
EU-94002, UKCCCR-ABC/BR9401, NCT00002580
Last Modified:
5/31/2007
2.
Phase III Randomized Study of Adjuvant Tamoxifen, Ovarian Suppression, and/or Chemotherapy in Women With Stage I, II, and IIIA Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Not specified
NCRI-ABC
CRC-TU-BR3010, SCTN-BR9401/BR9402, YRCO-ABC, EU-94029, UKCCCR-ABC, NCT00002582
Last Modified:
9/6/2006
3.
Phase III Randomized Study of Adjuvant Tamoxifen with vs without Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer 3 cm or Less in Diameter (Summary Last Modified 03/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
premenopausal
NCI
E-3193
CLB-9494, NCCTG-933252, SWOG-9347, INT-0142, E3193
Last Modified:
7/20/2007
 
First Published:
11/1/1994
4.
Phase III Randomized Study of Radiotherapy With or Without Neoadjuvant Flutamide Plus Goserelin or Leuprolide in Patients With Good Prognosis, Locally Confined Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Any age
NCI
RTOG-9408
NCT00002597, RTOG-94-08
Last Modified:
1/4/2007
 
First Published:
3/1/1995
5.
Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Under 80
NCI
CAN-NCIC-PR3
CALGB-9593, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, T94-0110, NCT00002633, PR3
Last Modified:
5/28/2008
6.
Phase III Randomized Study of Radical Prostatectomy with vs without Neoadjuvant Hormone Therapy Using Leuprolide or Goserelin and Flutamide or Bicalutamide for Stage I/II Prostate Cancer (Summary Last Modified 08/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 to 70
NCI
SWOG-S9615
SWOG-9615, S9615
Last Modified:
5/10/2007
 
First Published:
12/1/1996
7.
Phase III Randomized Study of Orchiectomy or LHRH Analogue Plus Flutamide With or Without Suramin and Hydrocortisone in Advanced Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
E-8892
CLB-E8892, SWOG-E8892, NCT00002881, E8892
Last Modified:
11/1/1998
8.
Phase III Study of Total Androgen Suppression Versus Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive Adenocarcinoma of the Prostate (Summary Last Modified 11/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
Not specified
NCI
RTOG-9608
RTOG-96-08
Last Modified:
5/22/2006
 
First Published:
1/1/1999
9.
Phase III Randomized Adjuvant Study of Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk of Recurrence
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Not specified
NCI
MDA-ID-97077
E-97077, NCI-T97-0069, NCT00003645, T97-0069
Last Modified:
2/23/2007
 
First Published:
1/1/1999
10.
Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
16 and over
NCI
CAN-NCIC-PR7
SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute